CD30L (N-18): sc-1734



The Power to Question

BACKGROUND

The tumor necrosis factor (TNF) receptor family is composed of several type I integral membrane glycoproteins that exhibit homology in their cystine-rich extracellular domains. Members of this family include FAS, OX40, CD27 and CD30. Ligands for these receptors are often type II transmembrane glycoproteins, as is the case for CD27 and CD30. CD27 is a homodimeric lymphocyte-specific surface antigen present on T and B lymphocytes. Activation of the CD3 complex via the T cell receptor for antigen leads to an increase in CD27 expression. Together, CD27 and its ligand, CD27L, generate costimulatory signals required for complete T cell activation. CD30 is a surface marker for neoplastic cells of the Hodgkin's lymphoma and related hematologic malignancies. CD30L has been shown to enhance the proliferation of the Hodgkin's cell line HDLM-2, but exerts antiproliferative effects on large cell anaplastic lymphoma cell lines.

REFERENCES

- 1. Smith, C.A., et al. 1993. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73: 1349-1360.
- Armitage, R.J. 1994. Tumor necrosis factor receptor superfamily members and their ligands. Curr. Opin. Immunol. 6: 407-413.
- 3. Hintzen, R.Q., et al. 1994. CD27: marker and mediator of T cell activation. Immunol. Today 15: 307-311.
- 4. Gruss, H.J., et al. 1995. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 85: 3378-3404.
- 5. Wendtner, C.M., et al. 1995. CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line. Cancer Res. 55: 4157-4161.
- 6. Lens, S.M., et al. 1995. CD27-CD70 interaction: unravelling its implication in normal and neoplastic B-cell growth. Leuk. Lymphoma 18: 51-59.
- 7. Bowen, M.A., et al. 1996. Structure and expression of murine CD30 and its role in cytokine production. J. Immunol. 156: 442-449.

CHROMOSOMAL LOCATION

Genetic locus: TNFSF8 (human) mapping to 9q32.

SOURCE

CD30L (N-18) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the N-terminus of CD30L of human origin.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with <0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-1734 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

CD30L (N-18) is recommended for detection of CD30L of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for CD30L siRNA (h): sc-42831, CD30L shRNA Plasmid (h): sc-42831-SH and CD30L shRNA (h) Lentiviral Particles: sc-42831-V.

Molecular Weight of CD30L: 40 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

SELECT PRODUCT CITATIONS

- Kamiyama, H. 2004. Herpes simplex virus-induced, death receptordependent apoptosis and regression of transplanted human cancers. Cancer Sci. 95: 990-998.
- 2. Shah, M., et al. 2010. A role for ATF2 in regulating MITF and melanoma development. PLoS Genet. 6: e1001258.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com